Dec 7, 2018

EMERGO BY UL SUMMARY OF KEY POINTS:

  • Health Canada’s December 31, 2018 deadline for MDSAP transition imminent.
  • Medical Device License (MDL) holders for Class II, III and IV devices must submit evidence of transition from CMDCAS to MDSAP by the December 31st deadline.

Health Canada has issued a final email reminder to medical device companies regarding the regulator’s December 31, 2018 deadline for transitioning to the Medical Device Single Audit Program (MDSAP) for quality management system compliance.

According to the Health Canada notice, all Medical Device License (MDL) holders of Class II, III and IV devices must provide evidence of MDSAP transition to the agency before December 31. Companies that fail to do so may face suspension of their MDLs. The regulator has published a MDSAP Frequently Asked Questions (FAQ) web page explaining documentation submission requirements.

MDSAP certification will replace the Canadian Medical Device Conformity Assessment System (CMDCAS) for quality management compliance starting in January 2019.

Related Health Canada and MDSAP regulatory resources from Emergo by UL:

  • CMDCAS, MDSAP and Health Canada ISO 13485 quality management system consulting
  • On-site MDSAP training for medical device manufacturers
  • Health Canada Medical Device License (MDL) registration consulting
  • Webinar: MDSAP certification overview
  • Whitepaper: Transitioning to MSDAP compliance

Author

  • Stewart Eisenhart

Related

Health Canada Developing MDL Policies for 3D-Printed Medical Devices

EMERGO SUMMARY OF KEY POINTS:

  • Health Canada to publish new guidance on MDL requirements for 3D-printed medical devices.
  • The Draft guidance will cover Class III and Class IV 3D-printed devices.
  • Publication expected in fall 2018.
Read more

Health Canada to Offer Pre-clinical Advisory Meetings to Medical Device Manufacturers

EMERGO SUMMARY OF KEY POINTS:

  • Health Canada’s Pre-Clinical Meeting program to provide feedback and recommendations to medical device manufacturers before they undertake clinical investigations.
  • Pre-Clinical Meeting program pilot to run from November 2018 to March 2019.
  • Formal Pre-Clinical Meeting guidance to be published following program pilot.
Read more

Canadian Regulators Launching Tailored Approach to Digital Health Technologies

EMERGO SUMMARY OF KEY POINTS:

  • Health Canada is establishing a new division for premarket review of digital health technologies.
  • The new Digital Health Review Division will handle licensing of wireless medical devices, mobile medical apps and related digital health products.
  • Health Canada plans to align its new division with similar digital health oversight initiatives by the US FDA and other regulators.
Read more

Have questions on what Emergo can do for you?

CONTACT US